Sanofi (SNY) Other Accumulated Expenses (2009 - 2021)

Sanofi has disclosed Other Accumulated Expenses across 13 years of filings, most recently posting $220.4 million for Q4 2021.

• Other Accumulated Expenses for Q4 2021 came in at $220.4 million, up 4.87% year-over-year; the trailing twelve-month figure through Dec 2021 was $220.4 million (up 4.87% YoY), and the FY2021 annual result was $228.0 million, up 13.29% from the prior year.
• Other Accumulated Expenses came in at $220.4 million for Q4 2021 at Sanofi, up from $210.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $10.8 billion in Q4 2017 to a low of $161.3 million in Q4 2019.
• The 5-year median for Other Accumulated Expenses is $220.4 million (2021), against an average of $4.6 billion.
• Across the five-year window, Other Accumulated Expenses soared 1984.99% in 2017 and slumped 98.13% in 2018, its largest moves.
• Sanofi's Other Accumulated Expenses stood at $10.8 billion in 2017, then sank by 98.24% to $191.0 million in 2018, then fell by 15.54% to $161.3 million in 2019, then surged by 30.34% to $210.2 million in 2020, then grew by 4.87% to $220.4 million in 2021.
• The last three Other Accumulated Expenses figures came in at $220.4 million (Q4 2021), $210.2 million (Q4 2020), and $161.3 million (Q4 2019), per Business Quant data.